Allogene Therapeutics Presents Preclinical Data On A Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 At The Society For Immunotherapy Of Cancer Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics, Inc. (NASDAQ:ALLO) presented preclinical data on a novel AlloCAR T product candidate targeting Claudin18.2 (CLDN18.2)-positive gastric and pancreatic tumors at the Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data suggests the potential to provide clinical benefit to patients with a single, off-the-shelf infusion. The preclinical evaluation identified candidates with potent activity in both short-term and repeat stimulation in vitro cytotoxicity assays. ALLO-182, currently in the IND-enabling phase of development, is based on these data.
November 03, 2023 | 4:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Allogene Therapeutics presented promising preclinical data on a novel AlloCAR T product candidate, potentially benefiting patients with gastric and pancreatic tumors. This could positively impact the company's stock in the short term.
The presentation of promising preclinical data on a novel product candidate can be seen as a positive development for the company. This could lead to increased investor confidence and a potential rise in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100